Should You Buy Pacific Biosciences of California, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Pacific Biosciences of California, Inc. (PACB) occupies a solid middle-ground position with a Quality of Company score of 5.6/10. At the current market price of $1.34, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 1 of 1 CirclFi valuation models project upside for Pacific Biosciences of California, Inc. (PACB) at $1.34 — the model consensus leans bullish, with a Quality Score of 5.6/10 and Value-Trap risk of 46/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Pacific Biosciences of California, Inc. (PACB) in 2026?
What Is the Bull Case vs the Bear Case for Pacific Biosciences of California, Inc. (PACB)?
| Bull case — $1.62 target (+20.6%) | Bear case |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $1.34 and the median fair value of $1.62 implies +20.6% upside potential. | No active model flags significant downside for PACB. The Value Trap score of 46/100 still argues for some caution. |
| According to the CirclFi Deep Alpha Valuation Engine, the PWERM model targets a fair value of $1.62 (+20.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | |
| Industry tailwind: regulatory pathway clarity could provide meaningful support for Pacific Biosciences of California, Inc.'s revenue and margin trajectory in the Medical Devices space. |
How Does PACB Compare to Its Medical Devices Peers?
Valuation data pages: QTI · NYXH · COCH · NNOX · VNRX · BMRA · MOBI · LIVN · SERA · IRMD · PODD
Which Other Stocks Score Like PACB on Quality?
Closest companies to PACB’s Quality of Company score of 5.6/10, across all industries.
- SCNI — Scinai Immunotherapeutics Ltd. (QOC 5.6) · analysis
- KLAR — Klarna Group plc (QOC 5.6) · analysis
- LIQT — LiqTech International, Inc. (QOC 5.6) · analysis
- FATE — Fate Therapeutics, Inc. (QOC 5.6) · analysis
- ALT — Altimmune, Inc. (QOC 5.6) · analysis
- BGSF — BGSF, Inc. (QOC 5.6) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does PACB Appear In?
So Is Pacific Biosciences of California, Inc. (PACB) Worth Buying in 2026?
The convergence of 5.6/10 quality, multi-model undervaluation (1/1 bullish, +20.6% median upside), and a median fair value of $1.62 vs. $1.34 current price makes Pacific Biosciences of California, Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Pacific Biosciences of California, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About PACB Stock?
Should I buy PACB stock right now?
Based on CirclFi's multi-model analysis, 1 of 1 models see upside for PACB at $1.34. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.6/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Pacific Biosciences of California, Inc.?
Key risks include: an elevated Value Trap score of 46/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does PACB compare to its competitors?
Among Medical Devices peers, PACB holds a Quality Score of 5.6/10. Comparable companies include QTI (QOC 5.6), NYXH (QOC 5.6), COCH (QOC 5.6). The relative ranking helps investors identify whether PACB offers better fundamental quality than alternatives in the same sector.
Is PACB a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PACB's Quality Score of 5.6/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy PACB at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $1.62 to $1.62. At $1.34, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for PACB.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad